TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 7865434

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 i.v. over 24 hours every 3 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel 200 to 250 mg/m2 i.v. over 24 hours every 3 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Cisplatin/etoposide chemotherapy (standard)
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel 135 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v.
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Paclitaxel 250 mg/m2 i.v. over 24 hours plus cisplatin 75 mg/m2 i.v. plus recombinant human granulocyte colony-stimulating factor
Number of subjects: 52
Study: 2494240

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 10 or 20 cm2 (5 or 10 mg/24 h) (Group A)
Number of subjects: 206

Group type: EXPERIMENTAL
Intervention: Transdermal nitroglycerin, 30 or 40 cm2 (15 or 20 mg/24 h) (Group B)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 206
Study: 31537025

Group type: EXPERIMENTAL
Intervention: Tamsulosin (0.4 mg/day)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Deflazacort (30 mg/day)
Number of subjects: 134

Group type: EXPERIMENTAL
Intervention: Combined treatment (Tamsulosin and Deflazacort)
Number of subjects: 134

Group type: COMPARATOR
Intervention: Paracetamol on demand (Control group)
Number of subjects: 134
Study: 31563255

Group type: EXPERIMENTAL
Intervention: Community pharmacist-led intervention
Number of subjects: 684

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 684
Study: 29208688

Group type: EXPERIMENTAL
Intervention: Interval-walking (IW; repeated cycles of 3 min slow [54% of VO2peak] and 3 min fast walking [89% of VO2peak])
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Continuous walking (CW; intended 73% of VO2peak)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Control
Number of subjects: 13
Study: 25062611

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 0.1×10^9 cfu/capsule/day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 1.0×10^9 cfu/capsule/day
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Bacillus subtilis R0179 at 10×10^9 cfu/capsule/day
Number of subjects: 81

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 81
Study: 24382526

Group type: EXPERIMENTAL
Intervention: Probiotic powder
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 21282540

Group type: EXPERIMENTAL
Intervention: Aspirin (ASA) 100 mg/d
Number of subjects: 667

Group type: EXPERIMENTAL
Intervention: Warfarin (WAR) 1.25 mg/d
Number of subjects: 667

Group type: COMPARATOR
Intervention: Low molecular weight heparin (LMWH) - Enoxaparin 40 mg/d
Number of subjects: 667
Study: 18164303

Group type: EXPERIMENTAL
Intervention: Goserelin (3.6 mg subcutaneous depot every 4 weeks for 3 doses)
Number of subjects: 66

Group type: COMPARATOR
Intervention: Leuprolide (3.75 mg subcutaneous depot every 4 weeks for 3 doses)
Number of subjects: 66
Study: 16474028

Group type: EXPERIMENTAL
Intervention: Rifapentine 900 mg/isoniazid 900 mg once weekly for 12 weeks
Number of subjects: 399

Group type: COMPARATOR
Intervention: Rifampin 450-600 mg/pyrazinamide 750-1,500 mg daily for 8 weeks
Number of subjects: 399

Group type: EXPERIMENTAL
Intervention: Rifapentine/isoniazid
Number of subjects: 399

Group type: COMPARATOR
Intervention: Rifampin/pyrazinamide
Number of subjects: 399
Study: 14563581

Group type: EXPERIMENTAL
Intervention: Intracoronary thrombectomy followed by stenting
Number of subjects: 92

Group type: COMPARATOR
Intervention: Conventional strategy of stenting
Number of subjects: 92
Study: 11028466

Group type: EXPERIMENTAL
Intervention: Diabetics
Number of subjects: 900

Group type: COMPARATOR
Intervention: Nondiabetics
Number of subjects: 900
Study: 8864797

Group type: EXPERIMENTAL
Intervention: Fenofibrate 250 mg retard capsules
Number of subjects: 20

Group type: COMPARATOR
Intervention: Lipanthyl 250 mg retard capsules
Number of subjects: 20
Study: 1617931

Group type: EXPERIMENTAL
Intervention: roxithromycin (150 mg b.i.d.)
Number of subjects: 96

Group type: COMPARATOR
Intervention: amoxicillin‐clavulanic acid (500 mg/125 mg t.i.d.)
Number of subjects: 96
Study: 6366550

Group type: EXPERIMENTAL
Intervention: Chemotherapy with fluorouracil and semustine
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Immunotherapy with methanol extraction residue of BCG
Number of subjects: 621

Group type: EXPERIMENTAL
Intervention: Combination therapy with fluorouracil, semustine, and immunotherapy
Number of subjects: 621

Group type: COMPARATOR
Intervention: Close follow-up without adjuvant treatment
Number of subjects: 621
Study: 29891538

Group type: EXPERIMENTAL
Intervention: NY-ESO-1c259T cells (autologous T cells expressing NY‐ESO‐1c259)
Number of subjects: 12
Study: 27393505

Group type: EXPERIMENTAL
Intervention: para-toluenesulfonamide (PTS) intratumoral injection
Number of subjects: 90
Study: 25694460

Group type: EXPERIMENTAL
Intervention: $10 Tim Hortons gift card
Number of subjects: 534

Group type: COMPARATOR
Intervention: Control group (no incentive)
Number of subjects: 534
Study: 22808940

Group type: EXPERIMENTAL
Intervention: Holistic yoga program (1 hour/day, for 12 weeks)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Physical exercise (1 hour/day, for 12 weeks)
Number of subjects: 90
Study: 20942940

Group type: EXPERIMENTAL
Intervention: Erythropoietin (Epo) 40,000 IU weekly infusions for 8 weeks
Number of subjects: 80

Group type: COMPARATOR
Intervention: Saline (NaCl 0.9%) weekly infusions for 8 weeks
Number of subjects: 80
Study: 18263856

Group type: EXPERIMENTAL
Intervention: Isocapnic hypoxia (IH)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Poikilocapnic hypoxia (PH)
Number of subjects: 10
Study: 16803917

Group type: EXPERIMENTAL
Intervention: Subarachnoid block (SAB) with bupivacaine, clonidine, and morphine
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Subarachnoid block (SAB)
Number of subjects: 89

Group type: COMPARATOR
Intervention: General anesthesia
Number of subjects: 89
Study: 12801618

Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 268
Study: 10875189

Group type: EXPERIMENTAL
Intervention: Progressive relaxation (PR) treatment for insomnia
Number of subjects: 118

Group type: COMPARATOR
Intervention: Untreated SWI
Number of subjects: 118

Group type: COMPARATOR
Intervention: Control group (SNI)
Number of subjects: 118
Study: 9663828

Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg t.d.s. for 6 months
Number of subjects: 14
Study: 8460798

Group type: EXPERIMENTAL
Intervention: Ondansetron 8 mg
Number of subjects: 243

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 243
Study: 3947124

Group type: EXPERIMENTAL
Intervention: Topical 5% minoxidil solution
Number of subjects: 47
Study: 30195949

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for conduct disorder (CD)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Polygenic risk scores (PRS) for attention-deficit hyperactivity disorder (ADHD)
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Parental monitoring
Number of subjects: 1050

Group type: EXPERIMENTAL
Intervention: Community disadvantage
Number of subjects: 1050
Study: 26851964

Group type: EXPERIMENTAL
Intervention: 10-min bout of moderate-intensity exercise
Number of subjects: 30

Group type: COMPARATOR
Intervention: Passive sitting
Number of subjects: 30
Study: 25204509

Group type: EXPERIMENTAL
Intervention: Landiolol 2 μg/kg/min (Group L2)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Landiolol 5 μg/kg/min (Group L5)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (Group C) - saline
Number of subjects: 40
Study: 24067398

Group type: EXPERIMENTAL
Intervention: Dexpramipexole 150 mg twice daily
Number of subjects: 943

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 943

Group type: EXPERIMENTAL
Intervention: Dexpramipexole
Number of subjects: 943
Study: 21422193

Group type: COMPARATOR
Intervention: Compression stockings (20-30 mmHg)
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sclerotherapy
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Sclerotherapy for residual telangiectasia
Number of subjects: 58
Study: 18294100

Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT)
Number of subjects: 13
Study: 16701199

Group type: EXPERIMENTAL
Intervention: Test lenses (unpolished lathe-cut posterior surface)
Number of subjects: 37

Group type: COMPARATOR
Intervention: Control lenses (polished lathe-cut posterior surface)
Number of subjects: 37
Study: 14552597

Group type: EXPERIMENTAL
Intervention: Kelman Z type multiflex Domi classic AC IOL
Number of subjects: 60

Group type: COMPARATOR
Intervention: Hanita lens with two eyelets (scleral fixated IOL)
Number of subjects: 60
Study: 10917405

Group type: EXPERIMENTAL
Intervention: Codeine 60 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine 120 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Codeine 180 mg
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinidine single-dose (50 mg)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Quinidine short-term (50 mg four times a day for 4 days)
Number of subjects: 12
Study: 8768938

Group type: EXPERIMENTAL
Intervention: Risperidone (2 < max <= 5 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Risperidone (higher than 15 mg)
Number of subjects: 2

Group type: EXPERIMENTAL
Intervention: Risperidone (higher than 10 mg)
Number of subjects: 2

Group type: COMPARATOR
Intervention: Haloperidol and perphenazine
Number of subjects: 2
Study: 1348750

Group type: EXPERIMENTAL
Intervention: Immediate intravenous beta‐adrenergic blocking agent therapy
Number of subjects: 3339

Group type: COMPARATOR
Intervention: Deferred beta‐blocker therapy
Number of subjects: 3339
Study: 2940091

Group type: EXPERIMENTAL
Intervention: beta-adrenoceptor blocker metoprolol (n = 88)
Number of subjects: 168

Group type: COMPARATOR
Intervention: thiazide diuretic hydrochlorothiazide (n = 80)
Number of subjects: 168

Group type: EXPERIMENTAL
Intervention: both regimens
Number of subjects: 168
Study: 31958417

Group type: EXPERIMENTAL
Intervention: Anti-thymocyte globulin plus standard GVHD prophylaxis
Number of subjects: 203

Group type: COMPARATOR
Intervention: Standard GVHD prophylaxis alone
Number of subjects: 203
Study: 29891218

Group type: EXPERIMENTAL
Intervention: WASH intervention and deworming
Number of subjects: 133

Group type: COMPARATOR
Intervention: Control group (only deworming)
Number of subjects: 133

Group type: EXPERIMENTAL
Intervention: Household water stored in covered containers
Number of subjects: 133
Study: 27554670

Group type: EXPERIMENTAL
Intervention: 1250 mg/day omega-3 fatty acid + alpha-tocopherol placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 400 IU/day alpha-tocopherol + omega-3 fatty acids placebo
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 1250 mg omega-3 fatty acids/day + 400 IU/day alpha-tocopherol
Number of subjects: 120

Group type: COMPARATOR
Intervention: omega-3 fatty acids placebo + alpha-tocopherol placebo
Number of subjects: 120
Study: 24647296

Group type: EXPERIMENTAL
Intervention: EMLA cream (Group A)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Oral sucrose (Group B)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Combination of EMLA cream and oral sucrose (Group C)
Number of subjects: 90
Study: 22590998

Group type: EXPERIMENTAL
Intervention: Vaginal preparation with povidone-iodine solution
Number of subjects: 670

Group type: COMPARATOR
Intervention: No vaginal preparation (control)
Number of subjects: 670
Study: 20217116

Group type: EXPERIMENTAL
Intervention: Sodium intake reduced to approximately 1,500 mg/day
Number of subjects: 136

Group type: COMPARATOR
Intervention: Habitual sodium intake of approximately 3,000 mg/day
Number of subjects: 136
Study: 18555934

Group type: EXPERIMENTAL
Intervention: Doripenem 500 mg IV q8h
Number of subjects: 476

Group type: COMPARATOR
Intervention: Meropenem 1 g IV q8h
Number of subjects: 476
Study: 19509118

Group type: EXPERIMENTAL
Intervention: Three-level cluster-randomized balanced designs
Number of subjects: 0
Study: 15004444

Group type: EXPERIMENTAL
Intervention: Acupuncture (AP) of the Pc 6 acupoint (group 1, n = 10)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Acupressure (APr) of the Pc 6 acupoint (group 2, n = 11)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo acupuncture (group 3, n = 8)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo acupressure (group 4, n = 7)
Number of subjects: 36
Study: 11571447

Group type: EXPERIMENTAL
Intervention: Daclizumab
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 9776435

Group type: EXPERIMENTAL
Intervention: Clonidine 2 microg x kg(‐1)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Clonidine 4 microg x kg(‐1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 30
Study: 7821474

Group type: EXPERIMENTAL
Intervention: Topical diclofenac 0.1% pretreatment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (no topical diclofenac)
Number of subjects: 0
Study: 3139310

Group type: EXPERIMENTAL
Intervention: Alfentanil - nitrous oxide
Number of subjects: 60

Group type: COMPARATOR
Intervention: Fentanyl - nitrous oxide
Number of subjects: 60
Study: 31462310

Group type: EXPERIMENTAL
Intervention: Si-ni-tang (SNT) 150 mL per day for 3 days
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline 150 mL per day for 3 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Si-ni-tang (SNT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Normal saline
Number of subjects: 0
Study: 30002931

Group type: EXPERIMENTAL
Intervention: Magnesium supplementation
Number of subjects: 200

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 200
Study: 27312248

Group type: EXPERIMENTAL
Intervention: Lateral pin fixation
Number of subjects: 62

Group type: COMPARATOR
Intervention: Medial-lateral pin fixation
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 62
Study: 23656441

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention (short duration <1 h) delivered in the workplace soon after discharge
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 21901285

Group type: EXPERIMENTAL
Intervention: BIB (BioEnterics Intragastric Balloon) for 6 months
Number of subjects: 50

Group type: COMPARATOR
Intervention: Sibutramine (pharmacotherapy) for 1 year
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BIB/lifestyle after BIB removal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BIB/pharmacotherapy after BIB removal
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: BIB/lifestyle or BIB/pharmacotherapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Pharmacotherapy group
Number of subjects: 50
Study: 19623780

Group type: EXPERIMENTAL
Intervention: Topical products designed to improve skin barrier function, hydration, and skin turnover
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Topical products
Number of subjects: 0
Study: 17327325

Group type: EXPERIMENTAL
Intervention: Optima Diab walker (group B)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Total contact casting (TCC; group A)
Number of subjects: 40
Study: 16095643

Group type: EXPERIMENTAL
Intervention: CQ + SP
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: MQ + AS
Number of subjects: 364

Group type: EXPERIMENTAL
Intervention: Coartem (lumefantrine + artemether)
Number of subjects: 364
Study: 12142121

Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) 400 microg administered via inhalation after intravenous N‐omega‐nitro‐monomethyl‐L‐arginine (L‐NMMA) 3 mg/kg over 5 min
Number of subjects: 33

Group type: COMPARATOR
Intervention: Salbutamol (Salb) 400 microg administered via inhalation after control solution (normal saline)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) after L‐NMMA
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Salbutamol (Salb) in CAD patients
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Glyceryl trinitrate (GTN) in CAD patients
Number of subjects: 33
Study: 10547221

Group type: EXPERIMENTAL
Intervention: Intracoronary ketanserin (1.5 mg in 10 ml normal saline administered over 3 min)
Number of subjects: 44

Group type: COMPARATOR
Intervention: Normal saline alone (control group)
Number of subjects: 44
Study: 7801853

Group type: EXPERIMENTAL
Intervention: Verapamil
Number of subjects: 104

Group type: COMPARATOR
Intervention: Metoprolol
Number of subjects: 104

Group type: COMPARATOR
Intervention: Both treatments
Number of subjects: 104
Study: 8703545

Group type: EXPERIMENTAL
Intervention: Postoperative radiation therapy with doses ranging from 45 to 50 Gy in the compartmental volume after complete resection, and from 55 to 60 Gy in the tumor bed after marginal or incomplete resection.
Number of subjects: 31
Study: 526382

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by fentanyl 1.25 or 2.5 microgram kg‐1 i.v.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by diazepam 0.0625 or 0.125 mg kg‐1 i.v.
Number of subjects: 104

Group type: COMPARATOR
Intervention: thiopentone preceded by fentanyl 1.25 microgram kg‐1 i.v.
Number of subjects: 104

Group type: EXPERIMENTAL
Intervention: etomidate 0.3 mg kg‐1 preceded by fentanyl 2.5 microgram kg‐1 i.v.
Number of subjects: 104
Study: 30120704

Group type: EXPERIMENTAL
Intervention: Images (perceptual form)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Audio recording or printed text (perceptual forms)
Number of subjects: 0
Study: 27853925

Group type: EXPERIMENTAL
Intervention: Fluoride gel applications with intensive dental prevention in kindergarten
Number of subjects: 6

Group type: COMPARATOR
Intervention: Fluoride gel applications without intensive dental prevention in kindergarten
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Maximum group prevention (intensive prevention in kindergarten and gel program at school)
Number of subjects: 6
Study: 25868203

Group type: EXPERIMENTAL
Intervention: Flurbiprofen axetil (FA) 1 mg x kg(‐1) administered at the end of surgery, n = 20
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control group (no FA administration), n = 20
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Both groups (FA and control)
Number of subjects: 40
Study: 23601744

Group type: EXPERIMENTAL
Intervention: 40 mg once daily (QD)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg twice daily (BID)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 30 mg BID
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 1 mg/kg QD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg QD
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 mg BID
Number of subjects: 80
Study: 21436467

Group type: EXPERIMENTAL
Intervention: Exercise performance at 579 ± 21 W (∼30 s)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exercise performance at work intensities ranging from 395 to 270 W (2.5‐21 min)
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Net rate of plasma K(+) accumulation during an ∼3‐min bout
Number of subjects: 7

Group type: EXPERIMENTAL
Intervention: Exhaustive exercise of ∼1‐4 min
Number of subjects: 7
Study: 19873917

Group type: EXPERIMENTAL
Intervention: He's Santong needling methods
Number of subjects: 180

Group type: COMPARATOR
Intervention: Oral administration of Cinnarizine, Cyproheptadine and Vitamin E
Number of subjects: 180
Study: 16625520

Group type: EXPERIMENTAL
Intervention: Experimental HIV vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 14988891

Group type: EXPERIMENTAL
Intervention: Left radial approach
Number of subjects: 437

Group type: COMPARATOR
Intervention: Right radial approach
Number of subjects: 437

Group type: EXPERIMENTAL
Intervention: Both approaches
Number of subjects: 437
Study: 11824022

Group type: EXPERIMENTAL
Intervention: Posterior pelvic exenteration with sacral resection
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Palliative operation
Number of subjects: 0
Study: 9741369

Group type: EXPERIMENTAL
Intervention: Theophylline (600 or 800 mg daily)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide (160 micrograms)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Combination of theophylline and ipratropium bromide
Number of subjects: 21

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study: 8041232

Group type: EXPERIMENTAL
Intervention: Cocaine HCl (1.25 and 1.9 mg/kg)
Number of subjects: 6

Group type: COMPARATOR
Intervention: Ethanol (0.85 g/kg)
Number of subjects: 6
Study: 3195055

Group type: EXPERIMENTAL
Intervention: NIVGRIP trivalent inactivated influenza vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 0
Study: 31267222

Group type: EXPERIMENTAL
Intervention: Antibiotics
Number of subjects: 125

Group type: COMPARATOR
Intervention: No antibiotics
Number of subjects: 125
Study: 29390493

Group type: EXPERIMENTAL
Intervention: Ping Chuan Ke Li (PCKL) plus oral montelukast
Number of subjects: 72

Group type: COMPARATOR
Intervention: Placebo plus oral montelukast
Number of subjects: 72
Study: 26188003

Group type: EXPERIMENTAL
Intervention: Sildenafil, 60 mg three times a day for 12 weeks
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 23763983

Group type: EXPERIMENTAL
Intervention: Physical activity intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fruit and vegetable consumption intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combined intervention (both physical activity and fruit and vegetable consumption)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-intervention control
Number of subjects: 0
Study: 21768458

Group type: EXPERIMENTAL
Intervention: Trastuzumab plus doxorubicin, cyclophosphamide, and paclitaxel
Number of subjects: 2

Group type: COMPARATOR
Intervention: Doxorubicin plus cyclophosphamide followed by paclitaxel
Number of subjects: 2
Study: 18807008

Group type: EXPERIMENTAL
Intervention: Sodium lactate
Number of subjects: 34

Group type: COMPARATOR
Intervention: Mannitol
Number of subjects: 34
Study: 17096718

Group type: EXPERIMENTAL
Intervention: HL-450 (0.45 g/100 mL)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: HL-350 (0.35 g/100 mL)
Number of subjects: 39

Group type: COMPARATOR
Intervention: HL-00 (regular formula)
Number of subjects: 39
Study: 15543442

Group type: EXPERIMENTAL
Intervention: AutoCITE intervention for 3 hours each weekday for 2 weeks
Number of subjects: 9

Group type: COMPARATOR
Intervention: Standard Constraint‐Induced Movement therapy (matched group of 12 subjects)
Number of subjects: 9